Thermo Fisher Scientific Inc. reported its financial results for the second quarter ended June 27, 2026, delivering broad-based growth across revenue, earnings, and operating margins. Revenue for the quarter grew 10% to $11.994 billion, versus $10.855 billion in the same quarter of 2025, supported by 5% organic revenue growth, a 5% contribution from acquisitions, and a 1% tailwind from currency translation. The company reported adjusted earnings per share (EPS) of $6.03, beating the analyst consensus estimate of $5.71 by 5.6%, representing a 13% increase from the prior year.

Key Second Quarter 2026 Highlights

The following table summarizes the headline financial metrics for the second quarter of 2026 compared to the second quarter of 2025:

"We delivered outstanding performance in the second quarter, reflecting the strength of our proven growth strategy, our team's excellent execution and the power of our PPI Business System," said Marc N. Casper, chairman and chief executive officer of Thermo Fisher Scientific. "Our end markets continue to strengthen and we're making great progress enhancing our capabilities, and further advancing our trusted partner status with customers, leading to continued share gain."

Business Segment Performance

The following table presents revenue and segment income margin by business segment for the three months ended June 27, 2026, compared to the three months ended June 28, 2025:

Laboratory Products and Biopharma Services remained the largest revenue contributor at 55.8% of consolidated revenues. Analytical Instruments demonstrated notable margin improvement, with segment income margin expanding to 23.0% from 18.8% in the prior-year quarter.

Growth Strategy and Capital Deployment

During the second quarter, Thermo Fisher Scientific advanced its growth strategy through a series of product launches and strategic initiatives:

• New product introductions: At the American Society for Mass Spectrometry conference, the company introduced next-generation Orbitrap platforms with AI-driven analytics, including the Thermo Scientific™ Orbitrap™ Tribrid™ Apex Mass Spectrometer and the Thermo Scientific™ Orbitrap™ Excedion™ Mass Spectrometer. The company also launched the Applied Biosystems™ PowerFlex™ Thermal Cycler, a next-generation PCR system.
• Commercial expansion: The company opened its flagship U.S. Bioprocess Design Center in Plainville, Massachusetts, expanding its global network of collaborative innovation hubs for pharma and biotech customers.
• Strategic collaboration: A strategic collaboration with Precision Health Research, Singapore was announced to support the PRECISE-SG100K population health study, leveraging integrated proteomics capabilities including Olink® technology and the Thermo Scientific™ Orbitrap™ Astral™ mass spectrometry system.
• Capital deployment: The company announced the divestiture of its microbiology business and repurchased $1.0 billion of stock during the quarter.

Six-Month Financial Summary

For the six months ended June 27, 2026, consolidated revenues were $22,999 million compared to $21,219 million in the prior-year period, representing 8% revenue growth. Organic revenue growth for the six-month period was 3%, with acquisitions contributing 4% and currency translation contributing 2%. GAAP diluted EPS for the six-month period was $9.10, compared to $8.26 in the prior-year period. Adjusted EPS (non-GAAP) for the six-month period was $11.47, compared to $10.51. Adjusted operating income for the six months ended June 27, 2026 was $5,133 million, with an adjusted operating margin of 22.3%, compared to $4,644 million and 21.9% in the prior-year period. Free cash flow for the six months ended June 27, 2026 was $2,503 million, compared to $1,479 million in the prior-year period.

Balance Sheet and Outlook

As of June 27, 2026, total assets stood at $113,174 million, compared to $110,343 million as of December 31, 2025. Cash and cash equivalents were $4,064 million, while long-term obligations were $39,181 million. Total equity was $52,686 million. The company indicated it would provide updated 2026 financial guidance during its earnings conference call held on July 23, 2026, at 8:30 a.m. Eastern Time. Thermo Fisher Scientific has annual revenue over $45 billion and serves customers across life sciences research, analytical challenges, laboratory productivity, diagnostics, and the development and manufacture of therapies.

Thermo Fisher Scientific has generated an average annual return of 14.23% over the past 20 years, outperforming the market by 4.97% on an annualized basis. The company currently commands a market capitalization of $197.73 billion. This performance highlights the impact of compounded returns on long-term wealth creation.

Investment Growth Analysis

The significant growth in shareholder value is illustrated by the performance of a hypothetical investment. If an investor had purchased $1000 of Thermo Fisher Scientific stock 20 years ago, that holding would be worth $14,418.43 today. This calculation is based on a current share price of $524.11.

Key Financial Metrics

The following table summarizes the financial performance and valuation metrics for Thermo Fisher Scientific based on the 20-year period:

The data underscores the substantial difference that compounded returns can make to cash growth over an extended investment horizon.